INmune Bio, Inc. (NASDAQ:INMB) Short Interest Update

INmune Bio, Inc. (NASDAQ:INMB - Get Free Report) saw a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 5,510,000 shares, a growth of 9.5% from the January 15th total of 5,030,000 shares. Based on an average daily volume of 330,500 shares, the days-to-cover ratio is presently 16.7 days.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in INMB. Financial Advocates Investment Management lifted its position in INmune Bio by 17.4% in the third quarter. Financial Advocates Investment Management now owns 13,500 shares of the company's stock worth $73,000 after purchasing an additional 2,000 shares during the period. Praetorian PR LLC boosted its stake in INmune Bio by 61.0% during the third quarter. Praetorian PR LLC now owns 780,800 shares of the company's stock valued at $4,209,000 after buying an additional 295,800 shares in the last quarter. State Street Corp boosted its stake in INmune Bio by 35.1% during the third quarter. State Street Corp now owns 226,428 shares of the company's stock valued at $1,220,000 after buying an additional 58,838 shares in the last quarter. Jane Street Group LLC acquired a new stake in INmune Bio in the 3rd quarter valued at about $79,000. Finally, XTX Topco Ltd bought a new position in shares of INmune Bio during the 3rd quarter valued at about $249,000. 12.72% of the stock is currently owned by institutional investors.

INmune Bio Trading Down 4.2 %

INMB traded down $0.40 on Thursday, reaching $9.09. The company had a trading volume of 216,547 shares, compared to its average volume of 484,086. INmune Bio has a one year low of $4.32 and a one year high of $13.52. The company has a market capitalization of $201.53 million, a P/E ratio of -4.17 and a beta of 1.87. The company has a fifty day moving average of $6.85 and a 200-day moving average of $6.14.

Analyst Ratings Changes

Several brokerages recently issued reports on INMB. Scotiabank raised their price target on INmune Bio from $22.00 to $23.00 and gave the stock a "sector outperform" rating in a report on Tuesday, February 11th. Maxim Group raised their target price on INmune Bio from $22.00 to $30.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. RODMAN&RENSHAW upgraded shares of INmune Bio to a "strong-buy" rating in a research report on Tuesday, January 28th. Finally, Rodman & Renshaw initiated coverage on shares of INmune Bio in a research report on Tuesday, January 28th. They issued a "buy" rating and a $23.00 price objective on the stock. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, INmune Bio currently has an average rating of "Buy" and a consensus target price of $22.80.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.